Jun 04, 2020
Mylan and Lupin Receive European Marketing Authorization for Nepexto®, Biosimilar Etanercept
Apr 01, 2020
Global Biosimilars Market (2020 to 2025) - New Indications and the Patent Expiry of Biologic Products Present Lucrative Opportunities
Mar 27, 2020
Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept
Mar 18, 2020
Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period
Jan 12, 2020
Mundipharma Enters Partnership With Samsung Bioepis to Expand Biosimilars Into Hong Kong and Taiwan
Dec 03, 2019
Abarca, Amgen Enter Outcome-Based Agreement For Enbrel
Sep 13, 2019
Novartis' Cosentyx and Pfizer's Xeljanz Leave the Most on the Table with Psoriatic Arthritis Switch Brands, According to Spherix Global Insights
Aug 26, 2019
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
Aug 09, 2019
Amgen Wins Patent Case On Enbrel® (etanercept)
Jul 30, 2019
Favorable Government Regulations Drove the US Biologics Market to be the Largest at $67 Billion in 2018: The Business Research Company
Jul 29, 2019
Alvotech and Cipla Gulf Enter Into a Partnership for the Commercialization of Key Biosimilar in Select Emerging Markets
Feb 06, 2019
The global rheumatoid arthritis drugs market will reach $47bn in 2024
Jan 22, 2019
Global Biosimilars Market 2017-2019 & 2024: Total of 492 Products in Development Featuring Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Pfizer, Samsung Bioepis & Sandoz
Jan 11, 2019
Visiongain Report Offers Transformative Insights on $47bn Rheumatoid Arthritis Market
Oct 26, 2018
Global Psoriasis Drugs Market to 2022: Increasing Preference for IL-inhibitor Therapy to Conventional TNF-inhibitors
Oct 24, 2018
First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
Sep 07, 2018
Global Biosimilar Market 2018-2023: Patent Expirees of Blockbuster Biological Drugs, Lower Prices, Rising Prevalence of Chronic Diseases, and Cost Saving Initiatives
Aug 20, 2018
US Rheumatologists' Early Views on Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer's Xeljanz Holds Ground as the Preferred JAK Inhibitor
Aug 10, 2018
TNF Inhibitors Market is Anticipated to Reach US$ 53,745.37 Mn by 2026, Says TMR
Jun 28, 2018
Lupin and Mylan Partner to Commercialize Enbrel® (Etanercept) Biosimilar